GlassScriptPhysician profile
Steven S Han
NPI 1205872231
$13,030.01
in general payments reported to CMS, 2019-2025
37 companies · $5,705 in 2025
The $5,705 reported for 2025 was more than what 94% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,204 · 2020: $1,025 · 2021: $740 · 2022: $1,079 · 2023: $1,382 · 2024: $1,895 · 2025: $5,705.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,648 · Consulting Fee: $3,259 · Education: $41.50 · Travel and Lodging: $33.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,647.87 |
| Consulting Fee | $3,259.20 |
| Education | $41.50 |
| Travel and Lodging | $33.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $3,591.97 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,904.09 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $723.95 | 2019-2025 | Tavneos, Uplizna, Aranesp |
| Bayer Healthcare Pharmaceuticals INC. | $689.29 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $675.07 | 2019-2025 | Jynarque, Voyxact |
| Vifor Pharma, INC. | $640.72 | 2019-2025 | Veltassa, Korsuva |
| Mallinckrodt Hospital Products INC. | $453.34 | 2020-2025 | Acthar |
| Lilly USA, LLC | $422.28 | 2023-2025 | Jardiance |
| Travere Therapeutics, INC. | $379.35 | 2023-2025 | Filspari |
| Akebia Therapeutics INC | $319.32 | 2019-2025 | Vafseo, Auryxia |
| Glaxosmithkline, LLC. | $283.25 | 2021-2025 | Benlysta, Jesduvroq |
| Ani Pharmaceuticals, INC. | $272.35 | 2022-2025 | Purified Cortrophin Gel |
| Fresenius USA Marketing, INC. | $263.12 | 2019-2025 | Velphoro, Velphoro |
| Novartis Pharmaceuticals Corporation | $254.92 | 2024-2025 | |
| Opko Pharmaceuticals, LLC | $254.49 | 2019-2025 | Rayaldee |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $231.06 | 2019-2025 | Ultomiris |
| Ardelyx, INC. | $218.66 | 2024-2025 | Ibsrela |
| Horizon Therapeutics Plc | $207.59 | 2019-2023 | Krystexxa |
| Kyowa Kirin, INC. | $164.61 | 2023-2025 | Crysvita |
| Stryker Corporation | $116.38 | 2025 | Artix Mt, Inthrill Thrombectomy Catheter, Clottriever Bold Catheter |
| Calliditas Therapeutics US INC. | $114.94 | 2025 | Tarpeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $112.41 | 2020-2023 | Gattex |
| Boston Scientific Corporation | $96.38 | 2023 | |
| Novo Nordisk INC | $85.48 | 2023-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.00 | 2024-2025 | Jardiance |
| Aurinia Pharma U.S., INC. | $73.00 | 2023-2025 | Lupkynis |
| Genzyme Corporation | $69.09 | 2022-2024 | |
| Ultragenyx Pharmaceutical INC. | $62.62 | 2020-2024 | Crysvita |
| Shire North American Group INC | $57.48 | 2019 | |
| Baxter Healthcare | $44.81 | 2019 | |
| Akcea Therapeutics, INC. | $41.13 | 2019 | |
| Scpharmaceuticals INC. | $35.41 | 2025 | |
| Apellis Pharmaceuticals, INC. | $23.13 | 2025 | Empaveli |
| Daiichi Sankyo INC. | $22.77 | 2023 | Injectafer |
| Mallinckrodt Enterprises LLC | $16.92 | 2019 | |
| Nxstage Medical, INC. | $14.72 | 2021 | |
| Genentech USA, INC. | $11.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Han listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.